These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1359050)

  • 1. Quantitative skin blanching assay of corticosteroid creams using tristimulus colour analysis.
    Chan SY; Li Wan Po A
    J Pharm Pharmacol; 1992 May; 44(5):371-8. PubMed ID: 1359050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of reflectance spectrophotometry in the human corticosteroid skin blanching assay.
    Conner DP; Zamani K; Almirez RG; Millora E; Nix D; Shah VP
    J Clin Pharmacol; 1993 Aug; 33(8):707-11. PubMed ID: 8408730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postural skin colour changes during the corticosteroid blanching assay.
    Henry F; Fumal I; Piérard GE
    Skin Pharmacol Appl Skin Physiol; 1999; 12(4):199-210. PubMed ID: 10420140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranking of glucocorticoid creams and ointments.
    Poulsen J; Rorsman H
    Acta Derm Venereol; 1980; 60(1):57-62. PubMed ID: 6153835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter.
    Queille-Roussel C; Poncet M; Schaefer H
    Br J Dermatol; 1991 Mar; 124(3):264-70. PubMed ID: 2018732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
    Schwarb FP; Smith EW; Haigh JM; Surber C
    Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling.
    Singh GJ; Adams WP; Lesko LJ; Shah VP; Molzon JA; Williams RL; Pershing LK
    Clin Pharmacol Ther; 1999 Oct; 66(4):346-57. PubMed ID: 10546918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of patients' satisfaction in using potent topical corticosteroid preparations.
    Shibata Y; Ikeda H; Kihira K
    Hiroshima J Med Sci; 2007 Dec; 56(3-4):33-9. PubMed ID: 18516932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of E
    Rath S; Zvidzayi M; Bon C; Kanfer I
    Basic Clin Pharmacol Toxicol; 2022 Sep; 131(3):165-173. PubMed ID: 35639025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of topical steroids.
    Barry BW
    Dermatologica; 1976; 152 Suppl 1():47-65. PubMed ID: 955238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of admixture of commercially available corticosteroid ointments and/or creams on vasoconstrictor activity].
    Ohtani M; Yamada N; Takayama K; Kotaki H; Etoh T; Kariya S; Uchino K; Iga T
    Yakugaku Zasshi; 2002 Jan; 122(1):107-12. PubMed ID: 11828745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments.
    Barry BW; Woodford R
    Br J Dermatol; 1975 Nov; 93(5):563-71. PubMed ID: 1203181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity?
    Gao HY; Li Wan Po A
    Eur J Clin Pharmacol; 1994; 46(1):71-5. PubMed ID: 8005190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the permeability of corticosteroid in hairless mouse and hairless micropig skin from admixture of commercially available corticosteroid ointments and/or creams].
    Ohtani M; Kotaki H; Kariya S; Uchino K; Iga T
    Yakugaku Zasshi; 2002 Aug; 122(8):589-94. PubMed ID: 12187775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.
    Barry BW; Woodford R
    Br J Dermatol; 1976 Oct; 95(4):423-5. PubMed ID: 974028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.
    Barry BW; Woodford R
    Br J Dermatol; 1974 Sep; 91(3):323-38. PubMed ID: 4611447
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: validation study using a chromameter.
    Keida T; Hayashi N; Kawashima M
    J Dermatol; 2006 Oct; 33(10):684-91. PubMed ID: 17040497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoconstrictive effect of topical applied corticosteroids measured by laser doppler imaging and reflectance spectroscopy.
    Sommer A; Lucassen GW; Houben AJ; Neumann MH
    Microvasc Res; 2003 May; 65(3):152-9. PubMed ID: 12711256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fitting Pharmacodynamic Data to the
    Tapfumaneyi P; Rath S; Bon C; Kanfer I
    Mol Pharm; 2022 Aug; 19(8):2900-2906. PubMed ID: 35763717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.